I like the last two paragraphs................... A biotechnology analyst at Paterson's Securities, Mathijs Smith, said he deal was good news for Biota but the market's response was an overeaction.
"The more panic there is about avian flu, the more the stockmarket over reacts to news like this"......... Biota is seeking to confirm the value of the French drug order as it is involved in litigation with the drug's licensee, GlaxoSmithKline.
